Conceivable Life Sciences secures $18m Series A for world-first automated IVF lab

ARTIS Ventures led the financing with participation from new and existing investors, raising over $39 million to date

Photo by Joshua Rodriguez on Unsplash

A biotech that promises to automate the IVF lab has today announced an $18million Series A financing round.

Conceivable Life Sciences will now further advance the development and commercialisation of the world’s first AI-powered automated IVF lab. The lab aims to make IVF more affordable for those who need it, increasing accessibility, while also improving outcomes.

ARTIS Ventures led the round with participation from new investors including Atlantic Health Venture Studio, Muse Capital, and Scrub Capital. Existing investors include ACME Capital, Black Opal Ventures, Cadence Healthcare Ventures, Future Positive Capital, Stride.VC, and Time BioVentures. Conceivable has raised over $39 million to date.

Automation in practice

Conceivable synthesizes AI and robotics to automate the more than 200 intricate steps required to create embryos for IVF, routinely performing delicate single cell surgery at the microscopic level.

The company achieved the world’s first fully automated intracytoplasmic sperm injection (ICSI), successfully performed both onsite and remotely, spanning 3,000 miles between the reproductive cells within Conceivable’s system and the embryologist operator in New York. This achievement was the subject of a mainstage presentation at the 2024 European Society of Human Reproduction and Embryology (ESHRE).

Dr. Alejandro Chavez-Badiola, reproductive endocrinologist, co-founder, and Chief Product Officer of Conceivable, said:

“Despite significant clinical advances since the first IVF child was born almost 50 years ago, IVF labs remain largely manual, artisanal, and lacking in the kind of automation and robotics that have transformed other branches of advanced medicine.”

“Our world class, interdisciplinary team of experts in embryology, automation, AI, robotics, advanced optics, and machine vision is transforming this outdated model. Even in early testing, our clinical outcomes rival the best IVF labs in the world. As we accelerate our program to expand access, we anticipate even better results, heralding a new chapter in IVF.”

US launch in 2026

The Series A financing will support a commercial pilot, which includes a 100-patient Institutional Review Board (IRB) study currently underway. In a prior IRB study using its first-generation AI and automation platform, 22 pregnancies were achieved upon the first embryo transfer. In addition to advancing its pilot, Conceivable will use the funding to prepare for a U.S. launch targeted for early 2026.

Alan Murray, co-founder and Chief Executive Officer of Conceivable said:

“I am incredibly proud of the scientific foundation, exceptional team, and encouraging data that we have achieved at Conceivable.”

“This funding allows us to build on our momentum with the support of leading investors who bring deep expertise in reproductive medicine.”

Joshua Abram, co-founder and Chairman of Conceivable said:

“We are honored to welcome ARTIS, Atlantic Health Venture Studio, Muse Capital, and Scrub Capital to our distinguished investor base.”

“Their confidence underscores the transformative potential of our technology to meet the immense and unmet demand for IVF globally.”

Stuart Peterson, founder and Managing Partner at ARTIS Ventures said:

“Conceivable’s approach to IVF, combining AI and cutting-edge robotics to create an entirely new 21st century model for IVF, will transform the field worldwide, catalyzing a new era of quality, scale, accessibility, and follow-on innovation.”

“Even in the U.S., 80% of infertile couples go untreated, unable to access IVF because of high cost, proximity to care, or both. Conceivable is creating a scalable solution that democratizes IVF and delivers equity in fertility care.”

Aike Ho, a Partner at ACME Capital who, with her wife, has undergone IVF using Conceivable technology said:

“Starting a family is a deeply personal and yet universal experience.”

“Our mission at Conceivable is to make IVF affordable to everyone who needs it. Given the high costs of IVF treatment today, this is not the reality. Conceivable’s innovation will radically increase accessibility to IVF and achieve better clinical outcomes for patients.”